Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12–49 (2024).

Article  PubMed  Google Scholar 

Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).

Article  CAS  PubMed  Google Scholar 

Shiu, K.-K. et al. LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study. Ann. Oncol. 34, S1271–S1272 (2023).

Article  Google Scholar 

Watanabe, J. et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329, 1271–1282 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cremolini, C. et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21, 497–507 (2020).

Article  CAS  PubMed  Google Scholar 

Van Cutsem, E. et al. ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. J. Clin. Oncol. 41, 2628–2637 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Hess, G. P., Wang, P. F., Quach, D., Barber, B. & Zhao, Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J. Oncol. Pract. 6, 301–307 (2010).

Article  PubMed  PubMed Central  Google Scholar 

Kennecke, H. et al. A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada. Curr. Oncol. 26, e748–e754 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLean, J. et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin. Colorectal Cancer 15, 135–140 (2016).

Article  PubMed  Google Scholar 

Rossini, D. et al. Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies. Eur. J. Cancer 170, 64–72 (2022).

Article  CAS  PubMed  Google Scholar 

Modest, D. P. et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J. Clin. Oncol. 33, 3718–3726 (2015).

Article  CAS  PubMed  Google Scholar 

Pietrantonio, F. et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann. Oncol. 28, 555–561 (2017).

Article  CAS  PubMed  Google Scholar 

Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).

Article  PubMed  Google Scholar 

Yoshino, T. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open 8, 101558 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).

Article  CAS  PubMed  Google Scholar 

Morris, V. K. et al. Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol. 41, 678–700 (2023).

Article  PubMed  Google Scholar 

Cervantes, A. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 10–32 (2023).

Article  CAS  PubMed  Google Scholar 

Cervantes, A. & Martinelli, E. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO metastatic colorectal cancer living guideline. Ann. Oncol. 35, 241–243 (2024).

Article  CAS  PubMed  Google Scholar 

Gubanski, M., Naucler, G., Almerud, A., Lideståhl, A. & Lind, P. A. R. M. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol. 44, 236–239 (2005).

Article  CAS  PubMed  Google Scholar 

Saif, M. W. et al. The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer. Res. 31, 2971–2974 (2011).

CAS  PubMed  Google Scholar 

Liu, Y. et al. Raltitrexed-based chemotherapy for advanced colorectal cancer. Clin. Res. Hepatol. Gastroenterol. 38, 219–225 (2014).

Article  CAS  PubMed  Google Scholar 

Rimassa, L. et al. Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori 92, 285–289 (2006).

Article  CAS  PubMed  Google Scholar 

Ferrarotto, R. et al. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur. J. Cancer 48, 820–826 (2012).

Article  CAS  PubMed  Google Scholar 

Mauri, G. et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities. Cancer Treat. Rev. 91, 102112 (2020).

Article  CAS  PubMed  Google Scholar 

Suenaga, M. et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des. Devel. Ther. 9, 3099–3108 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amatu, A. et al. Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: the RETROX-CRC retrospective study. Cancers 14, 1197 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303–312 (2013).

Article  CAS  PubMed  Google Scholar 

Li, J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16, 619–629 (2015).

Article  CAS  PubMed  Google Scholar 

Van Cutsem, E. et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study. Oncologist 24, 185–192 (2019).

Article  PubMed  Google Scholar 

Yeh, K.-H. et al. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. J. Formos. Med. Assoc. 120, 2023–2031 (2021).

Article  CAS  PubMed  Google Scholar 

Schulz, H. et al. Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: final results of the prospective multicentre non-interventional RECORA study. J. Clin. Oncol. 36, 748 (2018).

Article  Google Scholar 

Calcagno, F. et al. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in french clinical practice.